Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.

ABSTRACT:

Introduction

A combination of pemetrexed and cisplatin has been shown to improve the outcome in patients with malignant pleural mesothelioma (MPM), however, there is a great heterogeneity in treatment response among patients. The aim of our study was to evaluate the influence of polymorphisms in folate pathway and transporter genes on pemetrexed treatment outcome in Slovenian patients with MPM.

Methods

MPM patients treated with pemetrexed in the course of a prospective randomized clinical trial were genotyped for nineteen polymorphisms in five genes of folate pathway and six transporter genes. Logistic regression was used to assess the influence of polymorphisms on treatment efficacy and toxicity, while Cox regression was used to determine their influence on progression-free

SUBMITTER: Goricar K 

PROVIDER: S-EPMC4078035 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature